Mike Hollan

This acquisition will add asthma treatment A1O-001 to GSK’s portfolio.

Its path and application could model the same road as AI.

Harpreet Gill, vice president of real-world solutions - project management at ICON, discussesthe progress and challenges in advancing data-driven tools and approaches in decentralized clinical trials, where ongoing education remains paramount.

Bruce Phelan of Blue Fin discusses pharma’s need for access to manufacturing sites.

A new survey of pharma executives suggests that many are fully embracing the use of AI and are making financials plans based on the technology’s usage.

BioNTech will invest $200 million and get access to Autolus’ manufacturing sites.

According to the study conducted by Technavio, North America will contribute to 37% of the expected growth.

The three-year initiative comes with $15 million in funding.

The agreement will strengthen Novartis’ oncology pipeline.

The report predicts a 77% increase in global cancer cases by 2050.

The drugmaker will directly acquire three finish-fill sites as part of the deal.

The agency issued the warning against three brands of unapproved eyedrops designed to look like an approved brand.

The company has struggled to supply the drug to patients due to overwhelming popularity.

The shake is designed to work with regular dieters and those taking weight loss medications.

Researchers noted the onset of symptoms in patients who were treated with contaminated HGH therapy.

The agency recognized the medication as a significant advancement for the treatment of IPF.

Dr. Russo discusses how modern innovations will shape the way hospitals operate in years to come.

Sasser discusses how AI is directly helping with problems specific to precision and personalized medicine research.

The company states that no adverse events have been reported due to the contamination as of yet.

McCloskey discusses the steps that drug developers can take to ensure better CLD outcomes in 2024.

According to the university, new nanotech scaffolding can be used to support tissue growth.

Experts weigh in on recent trends regarding weight loss medication and how they expect those trends to evolve in the coming year.

The data was collected during the LEAP clinical program, developed in partnership with Merck.

As the technology becomes more ingrained within the Pharma industry’s processes, experts believe that regulation covering the use of AI is coming.

Investors may be attracted to precision medicine and gene therapy in the coming year due to a variety of reasons, including the treatments’ abilities to produce exact responses.

The device can produce AI-assisted readings.

The company also announced that it has submitted its new glucose monitoring system to the FDA for approval.

The survey is part of the brand’s new marketing campaign.

While the industry as a whole still faces challenges, there are positive trends appearing for pharmaceutical and medical device companies.

Both companies are now under the Norstella umbrella.